Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eszopiclone for insomnia in perimenopause/menopause
NCT00366093Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Feb 2004
- Primary completion
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Insomnia comparing Eszopiclone 3 mg with Placebo (2 arms). Primary endpoint: Mean Subjective Sleep Latency at Week 1. Started Feb 2004; status: completed.
02
Drugs
eszopiclone
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT00366093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00366093.